Sanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investment. New facility boosts Sanofi's Canadian vaccine manufacturing capacity.
| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2026 | 2.42 |
—
|
| 2025 | 2.20 |
—
|
| 2024 | 2.04 |
—
|
| 2023 | 1.90 |
—
|
| 2022 | 1.92 |
—
—
|
| 2021 | 1.93 |
—
|
| 2020 | 1.70 |
—
|
| 2019 | 1.72 |
—
|
| 2018 | 1.79 |
—
|
| 2017 | 1.64 |
—
|
| 2016 | 1.66 |
—
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 9,426.83 | 8,051.91 | 8,663.13 | 7,383.15 |
| Receivables | 9,550.22 | 9,090.72 | 9,964.24 | 10,703.82 |
| Inventory | 10,461.51 | 10,205.29 | 11,556.12 | 12,937.36 |
| Other | 3,755.58 | 4,140.12 | 4,600.27 | 4,978.68 |
| 33,194.14 | 46,084.48 | 35,019.09 | 36,650.63 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 7,931.09 | 8,170.94 | 8,328.24 | 8,313.31 |
| ST’ Debt | 2,213.30 | 4,554.56 | 4,912.54 | 8,169.13 |
| Other | 15,097.00 | 15,488.10 | 17,610.24 | 19,121.76 |
| 26,185.17 | 31,556.20 | 32,069.53 | 37,125.01 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 13,159.98 | 14,301.21 | — | — |
—
|
| ’25 | 11,173.42 | 12,186.37 | 15,394.41 | 14,100.27 |
52,854.48
|
| ’24 | 12,070.81 | 12,255.12 | 15,567.04 | 8,028.91 |
47,921.88
|
| ’23 | 11,660.34 | 11,647.65 | 13,820.50 | 13,137.84 |
50,266.34
|
| ’22 | 11,281.48 | 11,431.64 | 13,232.59 | 11,876.14 |
47,821.85
|
| ’21 | 10,712.96 | 20,636.90 | 12,769.56 | 23,211.36 |
46,347.94
|
| ’20 | 10,277.41 | 19,303.37 | 11,547.56 | 23,285.19 |
42,686.61
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | 5,398.42 | — | — |
—
|
| ’25 | 2,204.98 | 1,830.66 | — | 12,162.55 |
12,162.55
|
| ’24 | — | 1,532.43 | — | 9,826.55 |
9,826.55
|
| ’23 | — | 3,885.10 | — | 11,102.23 |
11,102.23
|
| ’22 | — | 3,984.38 | — | 11,090.19 |
11,090.19
|
| ’21 | — | 5,728.10 | — | 6,554.55 |
12,448.58
|
| ’20 | — | 4,411.24 | — | 4,349.38 |
8,508.99
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | 4,384.54 | — | — |
—
|
| ’25 | 2,204.98 | 711.35 | — | 9,117.95 |
9,117.95
|
| ’24 | — | 155.07 | — | 7,950.19 |
7,950.19
|
| ’23 | — | 3,501.27 | — | 8,927.89 |
8,927.89
|
| ’22 | — | 3,984.38 | — | 10,338.97 |
10,338.97
|
| ’21 | — | 4,861.77 | — | 6,554.55 |
10,880.97
|
| ’20 | — | 4,440.97 | — | 4,349.38 |
7,142.80
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.78 | 0.17 | — | — |
—
|
| ’25 | 0.80 | 1.84 | 1.34 | (0.38) |
3.62
|
| ’24 | 0.49 | 0.48 | 1.23 | 0.29 |
2.48
|
| ’23 | 0.86 | 0.63 | 1.11 | (0.24) |
2.33
|
| ’22 | 0.90 | 0.50 | 0.84 | 0.59 |
2.83
|
| ’21 | 0.75 | 2.63 | 1.09 | 3.11 |
2.94
|
| ’20 | 0.74 | 8.29 | 0.91 | 2.96 |
5.61
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 36.91 | 42.63 | 45.22 | 44.62 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 58.10 | 57.82 | 58.97 | 60.12 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 91,573 | 86,088 | 82,878 | 74,846 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.52 | 0.58 | 0.58 | 0.71 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 47,821.85 | 50,266.34 | 47,921.88 | 52,854.48 | — | — | — |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 69.83% | 69.35% | 70.18% | 72.07% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10,980.62 | 7,741.69 | 7,247.91 | 6,986.40 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 22.96% | 15.40% | 15.12% | 13.22% | — | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8,819.69 | 5,844.42 | 5,947.22 | 5,587.98 | — | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3,603.31 | 5,186.38 | 3,880.41 | 6,424.09 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 19.10 | 20.08 | 19.15 | 21.65 | — | — | — |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 2.83 | 2.33 | 2.48 | 3.62 | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.43 | 4.43 | 3.93 | 4.98 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.30) | (0.87) | (0.75) | (1.25) | — | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.13 | 3.57 | 3.18 | 3.74 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 31.62 | 32.15 | 33.66 | 33.24 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2,503.80 | 2,503.40 | 2,502.80 | 2,440.80 | — | — | — |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 17.31 | 21.19 | 19.37 | 13.46 | — | — | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.57 | 2.49 | 2.52 | 2.24 | — | — | — |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.55 | 1.56 | 1.43 | 1.46 | — | — | — |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 2.70 | 2.66 | 2.71 | 2.47 | — | — | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.01 | 5.16 | 6.33 | 7.02 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11,090.19 | 11,102.23 | 9,826.55 | 12,162.55 | — | — | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (751.22) | (2,174.34) | (1,876.36) | (3,044.60) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10,338.97 | 8,927.89 | 7,950.19 | 9,117.95 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10,601.32 | 7,008.97 | 14,528.28 | 2,949.56 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 20,051.06 | 17,741.06 | 17,313.60 | 21,032.73 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6,632.41 | 8,314.23 | 9,261.69 | 12,369.60 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 79,180.15 | 80,472.25 | 84,249.06 | 81,132.70 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.40% | 4.32% | 4.29% | 6.16% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.81% | 6.75% | 5.49% | 6.57% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.97% | 7.32% | 7.31% | 10.69% | — | — | — |
ROE
|
Sanofi’s decade-long financial journey showcases resilience amid volatility, with revenue growing from $38 billion in 2016 to $48 billion in 2024 at a 3% CAGR, boosted by Dupixent’s blockbuster success and COVID-19 vaccine sales, despite patent cliffs and a recent 5% dip. Efficiency gains shine through, as revenue per employee surged 63% to $584,000 amid a 20% headcount cut post-restructuring, driving gross margins toward 72% in 2025. A diversified portfolio in immunology, vaccines, and rare diseases has buffered pricing pressures and supply chain disruptions, positioning the pharma giant for a projected 10% revenue rebound to $53 billion next year.
Profitability fluctuated wildly—EBT hit 37% margins in 2020 before normalizing to 13-15%—yet free cash flow remains robust at $8 billion in 2024, funding reliable 5-6% dividends and capex. The balance sheet fortifies this strength, with equity up 32% to $84 billion, net debt trimmed 38% from peaks, and ample working capital for geopolitical risks. Valuation at 19x PE appears fair versus peers, with stock underperforming fundamentals but analyst targets implying 26% mean upside tied to Dupixent’s $10B run-rate and pipeline catalysts like tolebrutinib.
Forward momentum hinges on R&D ramps, cost savings, and organic 4-5% growth by 2028, tempered by U.S. pricing reforms and China exposure. Sanofi’s efficiency-driven rebound and mid-single-digit return potential make it compelling for value investors in a high-rate environment—explore the full analysis for deeper metrics and risks.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.